Milrinon Stragen (Milrinone)

Milrinone, the active ingredient in Milrinon Stragen, is a phosphodiesterase 3 inhibitor presented as a intravenous solution for intravenous use. It treats acute decompensated heart failure and cardiogenic shock in hospitalized patients. It is indicated for use in intensive care settings where rapid hemodynamic support is required.

GNH USA supplies Milrinon Stragen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and clinics worldwide, and is distributed to qualified healthcare institutions worldwide through regulated channels ensuring quality and compliance with EU standards.

Milrinone is used in the management of acute cardiac conditions that require inotropic support.

- Acute decompensated heart failure: improves cardiac output and reduces pulmonary congestion. - Cardiogenic shock: provides rapid increase in myocardial contractility and systemic perfusion. - Post‑cardiac surgery low cardiac output syndrome: helps maintain hemodynamic stability.

Milrinone may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Hypotension: lowered blood pressure due to vasodilation. - Arrhythmias: irregular heart rhythms, including tachycardia. - Headache: mild to moderate discomfort. - Nausea: gastrointestinal upset. - Flushing: warmth and redness of the skin. - Tachycardia: increased heart rate.

Serious or Rare Side Effects: - Severe hypotension: potentially life‑threatening drop in blood pressure. - Ventricular arrhythmias: dangerous heart rhythm disturbances. - Myocardial ischemia: reduced blood flow to heart muscle. - Thrombocytopenia: low platelet count. - Hepatic dysfunction: abnormal liver enzyme elevations. - Allergic reactions: rash, bronchospasm, or anaphylaxis.

Milrinone requires careful monitoring and specific safety measures before and during therapy.

- Monitor blood pressure: watch for hypotension. - Assess cardiac rhythm: risk of arrhythmias. - Use with caution in renal impairment: adjust dosing as needed. - Avoid in severe aortic stenosis: may worsen obstruction. - Evaluate for electrolyte abnormalities: especially potassium and magnesium. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Milrinone can interact with other medications, altering its efficacy or safety profile.

Major Interactions (Avoid): - Concurrent phosphodiesterase inhibitors: may cause excessive vasodilation. - Strong vasodilators (e.g., nitroglycerin): increase risk of severe hypotension. - Anti‑arrhythmic agents (e.g., amiodarone): heighten arrhythmia risk.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt inotropic response. - Diuretics: affect electrolyte balance, influencing cardiac stability. - Digoxin: potential additive effects on cardiac contractility.